Abivax (ABVX) Short term Debt (2021 - 2026)

Abivax's Short term Debt history runs 6 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $38.4 million in Q1 2026; TTM through Mar 2026 was $38.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $35.2 million, down 27.63% from the prior year.
• Short term Debt climbed to $38.4 million in Q1 2026 per ABVX's latest filing, from $35.2 million in the prior quarter.
• Across five years, Short term Debt topped out at $57.1 million in Q2 2025 and bottomed at $2.7 million in Q2 2024.
• The 5-year median for Short term Debt is $39.3 million (2023), against an average of $34.7 million.
• Across the five-year window, Short term Debt sank 72.32% in 2022 and surged 2036.23% in 2025, its largest moves.
• Year by year, Short term Debt stood at $3.6 million in 2022, then surged by 1018.62% to $40.2 million in 2023, then climbed by 19.49% to $48.0 million in 2024, then decreased by 26.7% to $35.2 million in 2025, then climbed by 8.98% to $38.4 million in 2026.
• Per Business Quant, the three latest ABVX Short term Debt figures stand at $38.4 million (Q1 2026), $35.2 million (Q4 2025), and $52.5 million (Q3 2025).